Analysis of Revenues
Advanced level
Revenues as Reported
Gilead Sciences Inc., Income Statement, Revenues
US$ in millions
| 12 months ended: | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Product sales | 24,355 | 22,119 | 21,677 | 25,662 | 29,953 |
Based on: 10-K (filing date: 2021-02-25), 10-K (filing date: 2020-02-25), 10-K (filing date: 2019-02-26), 10-K (filing date: 2018-02-27), 10-K (filing date: 2017-02-27).
| Item | Description | The company |
|---|---|---|
| Product sales | Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). | Gilead Sciences Inc.’s product sales increased from 2018 to 2019 and from 2019 to 2020. |